Lack of efficacy of clozapine monotherapy in refractory obsessive- compulsive disorder
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The authors assessed the efficacy of clozapine monotherapy for adults with treatment-resistant obsessive-compulsive disorder. METHOD: Twelve adults with refractory obsessive-compulsive disorder participated in a 10-week, open-label, systematic trial of clozapine. They were assessed with the Yale-Brown Obsessive Compulsive Scale, the Hamilton Depression Rating Scale, and the global improvement item of the Clinical Global Impression (CGI) scale. RESULTS: None of the 10 patients who completed the trial was a responder. No significant change was observed in obsessive-compulsive or depressive symptoms or in scores on the CGI global improvement item. CONCLUSIONS: These findings suggest that clozapine monotherapy is not effective for most adult patients with treatment-resistant obsessive-compulsive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Self-citationClozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
Self-citationThe yale global tic severity scale: initial testing of a clinician-rated scale of tic severity
LECKMAN, J. F., RIDDLE, M. A., HARDIN, M. T., ORT, S. I., SWARTZ, K. L., STEVENSON, J., & COHEN, D. J. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198907000-00015 · Cited by 2,146
Cited by
Tourette syndrome, associated conditions and the complexities of treatment
Robertson, M. M. (2000) · Brain · doi:10.1093/brain/123.3.425 · Cited by 704
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Self-citationEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
“The results for clozapine have been less encouraging (McDougle et al., 1995).”
Background(2004) · PubMed · Cited by 279
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275
“For example, the atypical neuroleptic clozapine, at doses (400– 500 mg/day) that would provide significant blockade of 5- HT2A receptors (Nordstrom et al, 1993), did not improve any of 10 treatment-refractory patients participating in a 10- week open-label trial (McDougle et al, 1995a).”
BackgroundSelf-citationObsessive–compulsive symptoms induced by atypical antipsychotics. A review of the reported cases
Lykouras, L., Alevizos, B., Michalopoulou, P., & Rabavilas, A. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00039-3 · Cited by 190
Neurobiology of Obsessive-Compulsive Disorder:Serotonin and Beyond
Westenberg, H. G. M., Fineberg, N. A., & Denys, D. (2007) · CNS Spectrums · doi:10.1017/s1092852900002479 · Cited by 148
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
“In a 6-week trial of open-label clozapine monotherapy in 12 highly treatment-refractory OCD subjects, no significant change was noted in the baseline measures in any of the 10 patients who completed the study (McDougle et al., 1995).”
BackgroundSerotoninergic mechanisms in the treatment of obsessive–compulsive disorder
Goddard, A. W., Shekhar, A., Whiteman, A. F., & McDougle, C. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.009 · Cited by 112
Self-citationFineberg, N. A., Stein, D. J., Premkumar, P., Carey, P., Sivakumaran, T., Vythilingum, B., Seedat, S., Westenberg, H., & Denys, D. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000215083.57801.11 · Cited by 103
“The beneficial effect of adding quetiapine to SRIs in OCD is intriguing as it is generally accepted that antipsychotics in monotherapy lack efficacy in OCD (McDougle et al., 1995; Connor et al., 2005).”
BackgroundBokor, G., & Anderson, P. D. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014521996 · Cited by 79
Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms?
Sareen, J., Kirshner, A., Lander, M., Kjernisted, K. D., Eleff, M. K., & Reiss, J. P. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.03.011 · Cited by 79
“However, a 10-week open label study of clozapine monotherapy in 12 adults with treatment-resistant OCD reported a lack of efficacy (McDougle et al., 1995).”
BackgroundInfluentialAssessing the validity of current mouse genetic models of obsessive-compulsive disorder
Wang, L., Simpson, H. B., & Dulawa, S. C. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832a80ad · Cited by 50
“, 2004) but not all human pharmacological challenge studies have shown that the 5-HT2B/ C agonist 1-(3-chlorophenyl)piperazine (m-CPP) exacerbates symptoms in OCD patients (McDougle et al., 1995; Khanna et al., 2001; de Leeuw and Westenberg, 2008).”
BackgroundRuiz (2000) · doi:10.1097/00131746-200005000-00002 · Cited by 14
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1995-12-01
- Volume
- 152
- Issue
- 12
- Pages
- 1812-1814
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2412109010
- Cited by
- 116
- References
- 4
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.